Heart failure & cardiomyopathies
Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction
Authors' conclusion
These results identify plasma signatures that are shared as well as potentially distinguish HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-programming were identified as unique signatures in the HFrEF group, possibly related to increased levels of BNP. Our results set the stage for future studies aimed at assessing selected metabolites as relevant biomarkers to guide HF phenotype-specific therapeutics.
Study context
- Population
- Subjects with HF with reduced ejection fraction (HFrEF), HFpEF and matched controls from the Penn Medicine BioBanksamples, 733 also underwent proteomic profiling
- Participants
- 787 samples
- Comparison
- HFrEF vs HFpEF vs matched controls
- HFrEFn = 219
- HFpEFn = 357
- Matched controlsn = 211
- Outcome
- Unsaturated medium-/long-chain acylcarnitines
Main finding
As reported in the abstract
- Elevated in the HFrEF group
Further findings
Amino acid derivatives (1- and 3-methylhistidine, homocitrulline, symmetric and asymmetric (ADMA) dimethylarginine)
- Elevated in heart failure (HF), with ADMA elevated uniquely in HFpEF
Branched-chain amino acids (BCAAs) and short-chain acylcarnitines indicative of BCAA catabolism
- BCAAs minimally changed; short-chain acylcarnitines elevated in both HF groups
3-HBA and C4-OH carnitine
- Uniquely elevated in the HFrEF group
Correlation between plasma 3-HBA and N-terminal pro-brain natriuretic peptide
- Significant correlation in both forms of HF, stronger in HFrEF
- Linear regression models
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →